Pentoxifylline in disorders involving hearing or dizziness.
Timothy C. Hain, MD
Please read our disclaimer
•Return to Index. •
Page last modified:
August 22, 2020
Treatment of vertebrobasilarr insufficiency (VBI) is largely based on reducing vascular risk factors and fluctuations in blood pressure. Pentoxifyllne, a drug used for intermittent claudication, has been tried by a few investigators for VBI. This is not at all a mainstream therapy for VBI, but it is also unlikely to be harmful.
Pentoxifylline is a prescription drug in the US.
Reports of the effect of Pentoxifylline on hearing disorders
Cesarone et al (2002)" The efficacy of Pentoxifylline in vascular inner ear disease (VIED) was studied comparing PXF and placebo in a 4-week study; 40 patients with vascular disease and monolateral loss of hearing, vertigo, dizziness, tinnitus (analyzed with an analogue scale line), and cochlear flow reduction were included. . Intention-to-treat analysis indicated an improvement in cochlear flow (p<0.05) and a decrease in score in both groups. The cochlear flow increase was 287.5% in the PXF group vs 168% in the placebo group (119.5% difference; p<0.02). There was a difference in score decrease (44.1% larger) in the PXF group (p<0.05).Between-group analysis favors PXF considering blood flow and symptoms. Results indicate good efficacy and tolerability of PXF in VIED. "
- de Barros et al (2003) reported on a small group of patients with SHL. There are no results in the abstract.
- Hartman and Tsuda (1988) reported improvement in vertigo and tinnitus in 90 patients with decreased cerebral blood flow.
Cleary et al (1999) reported dizziness as a side effect of crushed and intact pentoxifylline tablets.
- Brunelli, M. and S. Costantini (1989). "[Pentoxifylline in the treatment of vertiginous syndromes: clinical contribution]." Ric Clin Lab 19 Suppl 1: 129-131.
- Cesarone, M. R., et al. (2002). "Treatment of vascular inner ear disease in vascular patients with pentoxifylline: a controlled, randomized trial." Angiology 53 Suppl 1: S23-26.
- Cleary, J. D., et al. (1999). "Administration of crushed extended-release pentoxifylline tablets: bioavailability and adverse effects." Am J Health Syst Pharm 56(15): 1529-1534.
- de Barros, F. A., et al. (2003). "Audiological evaluation of twenty patients receiving pentoxifylline and prednisone after sudden deafness: prospective study." Int Tinnitus J 9(1): 17-22.
- Hartmann, A. and Y. Tsuda (1988). "A controlled study on the effect of pentoxifylline and an ergot alkaloid derivative on regional cerebral blood flow in patients with chronic cerebrovascular disease." Angiology 39(5): 449-457.
- Incandela, L., et al. (2002). "Treatment of vascular inner ear disease with pentoxifylline: a 4-week, controlled, randomized trial." Angiology 53 Suppl 1: S19-22. (this is the same as Cesarone et al).